Immunophenotype of neoplastic cells and association with EBV infection in the 219 LPHD cases
| Antigen . | Positive finding . | Number of nonassessable cases . | |
|---|---|---|---|
| No. . | % . | ||
| CD20 | 211 | 98 | 3 |
| CD79a | 172 | 80 | 4 |
| J-chain | 196 | 91.5 | 5 |
| CD30 | 0 | 0 | 0 |
| CD15 | 0 | 0 | 0 |
| EMA | 118 | 54 | 1 |
| EBER-transcripts | 0 | 0 | 45 |
| Antigen . | Positive finding . | Number of nonassessable cases . | |
|---|---|---|---|
| No. . | % . | ||
| CD20 | 211 | 98 | 3 |
| CD79a | 172 | 80 | 4 |
| J-chain | 196 | 91.5 | 5 |
| CD30 | 0 | 0 | 0 |
| CD15 | 0 | 0 | 0 |
| EMA | 118 | 54 | 1 |
| EBER-transcripts | 0 | 0 | 45 |
EBV, Epstein-Barr virus; LPHD, lymphocyte predominance Hodgkin disease; EMA, epithelial membrane antigen; EBER, EBV-encoded RNA.
The percentages have been calculated from evaluative cases.